Long-term Survival Analysis From PERLA, A Phase II Randomized Trial of Dostarlimab With Chemotherapy Versus Pembrolizumab With Chemotherapy in Metastatic Nonsquamous NSCLC

Introduction: PERLA is a global, double-blind, phase II trial comparing anti–programmed cell death protein 1 antibodies, dostarlimab, and pembrolizumab in combination with chemotherapy (D+CT and P+CT, respectively) in patients with metastatic nonsquamous NSCLC without actionable genomic aberrations...

Full description

Bibliographic Details

Published in:	JTO Clinical and Research Reports
Main Authors:	Sun Min Lim, MD, PhD, Ana Laura Ortega Granados, MD, Gustavo dix Junqueira Pinto, MD, MSc, Christian Sebastián Fuentes, MD, Giuseppe Lo Russo, MD, Michael Schenker, MD, Jin Seok Ahn, MD, PhD, Filippo de Marinis, MD, Kenneth Locke, Jr., PhD, Zsolt Szijgyarto, PhD, Elena Buss, MSc, Neda Stjepanovic, MD, PhD, Ivan Diaz-Padilla, MD, PhD, Solange Peters, MD, PhD
Format:	Article
Language:	English
Published:	Elsevier 2025-10-01
Subjects:	Dostarlimab Pembrolizumab NSCLC PD-1 receptor Immune checkpoint inhibitors
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666364325001183